Get started
TScan Therapeutics, Inc.TScan Therapeutics, Inc.TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TCRX chart


Full chart

TCRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪155.31 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−89.22 M‬ USD
Revenue (FY)
‪21.05 M‬ USD
Shares float
‪43.51 M‬
Beta (1Y)
1.77

Employees


Employees (FY)
154
Change (1Y)
+17 +12.41%
Revenue / Employee (1Y)
‪136.68 K‬ USD
Net income / Employee (1Y)
‪−579.34 K‬ USD

About TScan Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gavin MacBeath
Website
tscan.com
Headquarters
Waltham
Founded
2018
FIGI
BBG00PH1N007
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TCRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TCRX is 3.11 USD — it has decreased by −3.32% in the past 24 hours. Watch TScan Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TScan Therapeutics, Inc. stocks are traded under the ticker TCRX.
TCRX stock has fallen by −3.64% compared to the previous week, the month change is a −33.26% fall, over the last year TScan Therapeutics, Inc. has showed a −47.99% decrease.
We've gathered analysts' opinions on TScan Therapeutics, Inc. future price: according to them, TCRX price has a max estimate of 15.00 USD and a min estimate of 7.00 USD. Watch TCRX chart and read a more detailed TScan Therapeutics, Inc. stock forecast: see what analysts think of TScan Therapeutics, Inc. and suggest that you do with its stocks.
TCRX reached its all-time high on Aug 18, 2021 with the price of 14.71 USD, and its all-time low was 1.45 USD and was reached on Dec 27, 2022. View more price dynamics on TCRX chart.
See other stocks reaching their highest and lowest prices.
TCRX stock is 17.57% volatile and has beta coefficient of 1.77. Track TScan Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TScan Therapeutics, Inc. there?
Today TScan Therapeutics, Inc. has the market capitalization of ‪155.31 M‬, it has increased by 0.34% over the last week.
Yes, you can track TScan Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TScan Therapeutics, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
TCRX earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.32 USD resulting in a 20.73% surprise. The estimated earnings for the next quarter are −0.32 USD per share. See more details about TScan Therapeutics, Inc. earnings.
TScan Therapeutics, Inc. revenue for the last quarter amounts to ‪1.05 M‬ USD, despite the estimated figure of ‪1.17 M‬ USD. In the next quarter, revenue is expected to reach ‪1.52 M‬ USD.
TCRX net income for the last quarter is ‪−29.89 M‬ USD, while the quarter before that showed ‪−31.66 M‬ USD of net income which accounts for 5.60% change. Track more TScan Therapeutics, Inc. financial stats to get the full picture.
No, TCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 154.00 employees. See our rating of the largest employees — is TScan Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TScan Therapeutics, Inc. EBITDA is ‪−114.79 M‬ USD, and current EBITDA margin is −418.53%. See more stats in TScan Therapeutics, Inc. financial statements.
Like other stocks, TCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TScan Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TScan Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TScan Therapeutics, Inc. stock shows the strong sell signal. See more of TScan Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.